Om

Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra-tunable peptide therapeutics designed to modulate intracellular proteins that are traditionally difficult to target with conventional medicines. Its proprietary Helicon platform combines AI-driven design, high-throughput synthesis, and experimental screening to create stabilized helical peptides for precision drug development. The company’s current pipeline includes investigational programs for serious diseases such as cancer and other complex conditions, with lead efforts centered on zolucatetide, a direct inhibitor of the β-catenin:TCF interaction in the Wnt/β-catenin pathway. Parabilis Medicines also advances additional programs in targeted protein degradation and other intracellular mechanisms, reflecting its role in expanding the therapeutic reach of peptide-based medicines across oncology and related disease areas.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I PARABILIS MEDICINES MED ENDAVU: Køb Parabilis Medicines ($PBLS) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Parabilis Medicines, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.